GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (SHSE:600196) » Definitions » PEG Ratio

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) PEG Ratio : 6.08 (As of May. 02, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Shanghai Fosun Pharmaceutical (Group) Co's PE Ratio without NRI is 26.15. Shanghai Fosun Pharmaceutical (Group) Co's 5-Year EBITDA growth rate is 4.30%. Therefore, Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio for today is 6.08.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio or its related term are showing as below:

SHSE:600196' s PEG Ratio Range Over the Past 10 Years
Min: 0.64   Med: 3.55   Max: 371.35
Current: 5.09


During the past 13 years, Shanghai Fosun Pharmaceutical (Group) Co's highest PEG Ratio was 371.35. The lowest was 0.64. And the median was 3.55.


SHSE:600196's PEG Ratio is ranked worse than
81.13% of 371 companies
in the Drug Manufacturers industry
Industry Median: 1.72 vs SHSE:600196: 5.09

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.92 3.58 11.63

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 2.61 3.56 11.63 -

Competitive Comparison of Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio falls into.



Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=26.154696132597/4.30
=6.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Shanghai Fosun Pharmaceutical (Group) Co  (SHSE:600196) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Shanghai Fosun Pharmaceutical (Group) Co PEG Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Business Description

Traded in Other Exchanges
Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Headlines

No Headlines